• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CollabRx, University of Chicago collaborate

CollabRx, University of Chicago collaborate

June 19, 2013
CenterWatch Staff

CollabRx data analytics, focused on informing clinical decision making in molecular medicine, is collaborating with the thoracic oncology program at the University of Chicago Medical Center, a cancer treatment center with clinical and translational research programs in cancer genetics and therapeutics.

The initiative will combine CollabRx content and technology resources with the results of genetic sequencing-based tests conducted at the medical center. The tests are designed to enable physicians to consider a tumor's unique genetic profile in cancer treatment planning.

"This commitment includes consideration of drugs and other therapies that target genetic abnormalities in tumors,” said Ravi Salgia, M.D., Ph.D., vice chair of translational research at the University of Chicago and collaboration leader. “These genetic abnormalities can now be efficiently identified using cancer mutation panels based on next generation sequencing technologies. CollabRx's systems add substantial value to these panels by infusing interpretation and insight from recognized thought leaders who have knowledge of the latest scientific and medical research in molecular oncology and, more importantly, understand how to apply this knowledge to inform treatment planning at the point of care.”

CollabRx will provide a turnkey medical informatics solution by pairing the results of cancer mutational panels conducted by Salgia and colleagues at the medical center with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials. It also is supported by CollabRx's network of over 75 experts and clinical practitioners in the U.S. and Europe.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing